New imaging approach offers unprecedented views of staph infection
(Vanderbilt University Medical Center) Eric Skaar, Ph.D., M.P.H., and colleagues at Vanderbilt have combined multiple types of molecular imaging to probe an invasive Staphylococcus aureus infection in the mouse. Their integrated imaging approach, reported this week in Science Translational Medicine, revealed new insights about staph infections and can be broadly applied to any health or disease state. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 14, 2018 Category: Infectious Diseases Source Type: news
Research project on dangerous hospital germ extended
(Goethe University Frankfurt) Cases of multi-resistant bacteria in hospitals have increased dramatically in recent years and the health system faces tremendous problems as a result. Alongside 'old acquaintances', such as Staphylococcus aureus (MRSA) or Klebsiella pneumonia, another pathogen has now arrived on the scene: Acinetobacter baumannii. In order to find new weapons for the fight against this aggressive germ, in 2014 the German Research Foundation established a Research Unit led by Goethe University Frankfurt which has now been extended for a further three years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 7, 2018 Category: International Medicine & Public Health Source Type: news
Nerve cells found to suppress immune response during deadly lung infections
(Harvard Medical School) Neurons that carry nerve signals to and from the lungs suppress immune response during fatal lung infections with the bacterium Staphylococcus aureus.Animal experiments show that disabling these neurons can boost immune response and promote bacterial clearance to aid recovery.Targeting neuro-immune signaling in the lungs can pave the way to nonantibiotic therapies for bacterial pneumonia. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 5, 2018 Category: Infectious Diseases Source Type: news
Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.
This research article has led to a Practice Changing Update on DynaMed Plus. It concludes that adjunctive rifampicin may not reduce composite outcome of risk of treatment failure or disease recurrence and mortality in patients on active antibiotic treatment for S. aureus bacteremia. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 23, 2018 Category: Consumer Health News Source Type: news
A Potentially Powerful New Antibiotic Is Discovered in Dirt
The world is facing an epidemic of infections that no longer respond well to the drugs used to treat them—also known as super bugs. In the United States, an estimated 2 million Americans are diagnosed each year with an infection that doesn’t respond to antibiotics, and 23,000 will die from those infections. But New York and New Jersey researchers published a new paper in the journal Nature Microbiology about their hopeful discovery: a potentially new class of antibiotic that they found in dirt.
In the lab, the researchers used a method to extract, clone and sequence DNA from soil samples to see if there are gen...
Source: TIME: Health - February 14, 2018 Category: Consumer Health News Authors: Alexandra Sifferlin Tags: Uncategorized healthytime public health Source Type: news
New research suggests your immune system can protect against MRSA infections
After years of investigation, researchers at Johns Hopkins, the University of California, Davis, and the National Institute of Allergy and Infectious Diseases have discovered how the immune system might protect a person from recurrent bacterial skin infections caused by Staphylococcus aureus (staph). The findings, publishing online in The Journal of Clinical Investigation, open new doors to someday developing vaccines to prevent staph skin infections, which account for 14 million outpatient visits, nearly 500,000 hospital admissions and $3 billion to $4 billion in inpatient health care costs in the U.S. per year. (Source: World Pharma News)
Source: World Pharma News - February 5, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
New research suggests your immune system can protect against MRSA infections
(Johns Hopkins Medicine) After years of investigation, researchers at Johns Hopkins, the University of California, Davis, and the National Institute of Allergy and Infectious Diseases have discovered how the immune system might protect a person from recurrent bacterial skin infections caused by Staphylococcus aureus (staph). (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 5, 2018 Category: Infectious Diseases Source Type: news
FDA OKs First Vancomycin Oral Solution for C diff Diarrhea FDA OKs First Vancomycin Oral Solution for C diff Diarrhea
Vancomycin hydrochloride for oral solution (Firvanq) is for treatment of Clostridium difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 30, 2018 Category: Consumer Health News Tags: Infectious Diseases News Alert Source Type: news
High levels of antibiotic resistance found worldwide, new data show
BANGKOK 29 January 2018 – The World Health Organization’s first release of surveillance data on antibiotic resistance reveals high levels of resistance to a number of serious bacterial infections in both high- and low-income countries.
WHO’s new Global Antimicrobial Surveillance System (known as GLASS) reveals widespread occurrence of antibiotic resistance among 500 000 people with suspected bacterial infections across 22 countries.
The most commonly reported resistant bacteria were Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pneumoniae, followed by Salmonella spp. T...
Source: WHO EMRO News - January 29, 2018 Category: Middle East Health Source Type: news
CutisPharma Announces FDA Approval of Firvanq (vancomycin) for Treatment of Clostridium Difficile Associated Diarrhea and Staphylococcus Aureus Colitis
WILMINGTON, Mass. (Jan. 29, 2018) – CutisPharma announced today that the US Food and Drug Administration (FDA) has approved Firvanq (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 29, 2018 Category: Drugs & Pharmacology Source Type: news
Adjunctive Rifampin Not Beneficial for Staph aureus Bacteremia Adjunctive Rifampin Not Beneficial for Staph aureus Bacteremia
Adjunctive rifampin, also called rifampicin, provides no significant benefit over standard antibiotic therapy in patients with Staphylococcus aureus bacteremia, according to results from the ARREST trial.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 29, 2017 Category: Intensive Care Tags: Infectious Diseases News Source Type: news
Aiding and abetting Staphylococcus aureus
(Source: ScienceNOW)
Source: ScienceNOW - December 21, 2017 Category: Science Authors: Ash, C. Tags: twil Source Type: news
Medimetriks Pharmaceuticals, Inc. Receives FDA Approval for Xepi(TM) (ozenoxacin) Cream, 1%, a Novel Topical Antibiotic for Impetigo
Bactericidal antibiotic cream indicated for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older
Demonstrated activity against most isolates both in vitro and in clini... Biopharmaceuticals, Dermatology, FDA Medimetriks Pharmaceuticals, Xepi, ozenoxacin, Impetigo (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 14, 2017 Category: Pharmaceuticals Source Type: news
Kent State researcher exposes MRSA risk at northeast Ohio beaches
(Kent State University) Tara C. Smith, Ph.D., a professor of epidemiology in Kent State's College of Public Health, published the findings of a study her lab conducted in 2015 that shows a higher-than-expected prevalence of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA) at beaches around Lake Erie. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 14, 2017 Category: Infectious Diseases Source Type: news
Boosting the antibiotic arsenal
(Massachusetts Institute of Technology) MIT researchers have discovered a way to make bacteria more vulnerable to a class of antibiotics known as quinolones, which include ciprofloxacin and are often used to treat infections such as Escherichia coli and Staphylococcus aureus. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 8, 2017 Category: International Medicine & Public Health Source Type: news
